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ABSTRACT
Podocalyxin (PODXL) overexpression is associated with progression, metastasis, 
and poor outcomes in cancers. We recently produced the novel anti-PODXL monoclonal 
antibody (mAb) PcMab-47 (IgG1, kappa). Herein, we engineered PcMab-47 into 47-
mG2a, a mouse IgG2a-type mAb, to add antibody-dependent cellular cytotoxicity 
(ADCC). We further developed 47-mG2a-f, a core fucose-deficient type of 47-mG2a 
to augment its ADCC. Immunohistochemical analysis of oral cancer tissues using 
PcMab-47 and 47-mG2a revealed that the latter stained oral squamous cell carcinoma 
(OSCC) cells in a cytoplasmic pattern at a much lower concentration. PcMab-47 and 
47-mG2a detected PODXL in 163/201 (81.1%) and in 197/201 (98.0%) OSCC samples, 
respectively. 47-mG2a-f also detected PODXL in OSCCs at a similar frequency as 47-
mG2a. In vitro analysis revealed that both 47-mG2a and 47-mG2a-f exhibited strong 
complement-dependent cytotoxicity (CDC) against CHO/hPODXL cells. In contrast, 
47-mG2a-f exhibited much stronger ADCC than 47-mG2a against OSCC cells, indicating 
that ADCC and CDC of those anti-PODXL mAbs depend on target cells. In vivo analysis 
revealed that both 47-mG2a and 47-mG2a-f exerted antitumor activity in CHO/hPODXL 
xenograft models at a dose of 100 μg or 500 μg/mouse/week administered twice. 
47-mG2a-f, but not 47-mG2a, exerted antitumor activity in SAS and HSC-2 xenograft 
models at a dose of 100 μg/mouse/week administered three times. Although both 
47-mG2a and 47-mG2a-f exerted antitumor activity in HSC-2 xenograft models at a dose 
of 500 μg/mouse/week administered twice, 47-mG2a-f also showed higher antitumor 
activity than 47-mG2a. These results suggested that a core fucose-deficient anti-PODXL 
mAb could be useful for antibody-based therapy against PODXL-expressing OSCCs.
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INTRODUCTION
In total, 300,000 cases of oral cancer are reported 
annually, constituting approximately 2% of all cancer 
cases globally [1], and several histological tumor types 
exist, including squamous cell carcinoma (OSCC), 
adenoid cystic carcinoma, mucoepidermoid carcinoma, 
and osteosarcoma. Among them, almost 90% of oral 
cancers are OSCCs [2]. The most common location of 
OSCC is the tongue, accounting for approximately 40% 
of OSCCs [3, 4]. Despite improvements in diagnostic 
technology and therapeutic techniques, the survival rate 
of OSCC has improved by only 5% over the past 20 years. 
Consequently, the 5-year survival rate is 60% [5], and the 
incidence of OSCC has increased globally [4, 6].
OSCC is mainly treated via surgical removal, 
which can be complemented by radiotherapy and/or 
chemotherapy, especially in advanced stages. Many 
types of anticancer agents, including cisplatin (CDDP), 
5-fluorouracil (5-FU), and docetaxel, are used for 
chemotherapy [7, 8]. In contrast, the availability of 
approved molecular targeting drugs with efficacy against 
OSCC is limited. Recently, cetuximab, a mouse-human 
(IgG1) chimeric antibody against epidermal growth 
factor receptor (EGFR), was approved for treating head 
and neck cancer (HNC) including oral cancer. In several 
clinical studies, cetuximab was found to be effective 
against locoregionally advanced head and neck squamous 
cell carcinoma (HNSCC) or recurrent and/or metastatic 
(R/M) HNSCC [7, 9-11]. Furthermore, nivolumab, a fully 
human IgG4 mAb against programmed cell death-1, was 
also approved for the treatment of R/M HNC, which has 
been treated with platinum-based chemotherapy [12]. In 
addition, bevacizumab, which is a mouse-human IgG1 
chimeric antibody against vascular endothelial growth 
factor (VEGF) and first approved for colorectal cancer, 
had some clinical trial in which R/M HNSCC patients 
were enrolled [13]. Because molecular targeting drugs that 
are clinically applicable for oral cancers are limited, novel 
drugs with greater efficacy and lower toxicity are required. 
Therefore, we have been investigating several membrane 
proteins, and we developed several mAbs against those 
targets, including HER2 [14], EGFR [15], podoplanin 
[16], and PODXL [17].
Podocalyxin (PODXL) is a type I transmembrane 
protein with a molecular weight of 150,000–200,000 
[18-20], and it is also known as PCLP, MEP21, Gp200, 
Gp135, thrombomucin, GCTM2, TRA-1-60 antigen, and 
TRA-1-81 antigen. PODXL is highly glycosylated with 
N- and O-glycans [21]. It can be found in kidney, heart, 
pancreatic, and breast tissues, and it plays important roles 
in the development of some tissues [22]. PODXL is also 
a pluripotent stem cell marker [23-26]. Furthermore, it is 
a diagnostic marker and a prognostic indicator for certain 
cancers such as brain tumors [21], colorectal cancer 
[27], renal cancer [28], and oral cancer [29]. Moreover, 
PODXL has been suggested to promote tumor growth, 
invasion, and metastasis [30, 31]; accordingly, high 
PODXL expression could have adverse effects on overall 
survival (OS), disease-specific survival (DSS), and 
disease-free survival (DFS) in several cancers. PODXL is 
overexpressed in the aforementioned cancers, identifying 
the protein as a potential target for antibody therapy.
Despite the development of anti-PODXL monoclonal 
antibodies (mAbs) [32, 33], the efficacy of these treatments 
against oral cancers remains to be fully elucidated. We 
previously immunized mice with recombinant PODXL, 
which was purified from the culture supernatant of LN229/
ectodomain-PODXL cells [17]. One clone, PcMab-47 
(mouse IgG1, kappa), was successfully produced. We further 
produced chPcMab-47 from PcMab-47 and investigated its 
antitumor activity against colorectal cancers [34]. In those 
studies, we injected human NK cells around the tumors to 
investigate antitumor activity because chPcMab-47 could 
not induce ADCC activity using mouse NK cells. Although 
chPcMab-47 significantly reduced tumor development 
compared with the effects of control human IgG, its 
antitumor activity might not be sufficient for antibody-
based target therapy. We used human NK cells from one 
donor; therefore, the cause of the low antitumor activity is 
due to differences in the sources of cells. Because we had to 
inject human NK cells around the subcutaneous tumors of 
xenograft models several times, we experienced difficulties 
in measuring tumor diameters because the tumor shape 
sometimes changed post-injection. Furthermore, mouse 
IgG1 does not induce ADCC and CDC, and PcMab-47 was 
determined to be IgG1. In this study, we established the 
47-mG2a, a chimeric anti-PODXL antibody by combining 
variable region of PcMab-47 and constant region of mouse 
IgG2a. We further produced 47-mG2a-f, a core fucose-
deficient 47-mG2a to analyze antitumor activity in xenograft 
models [35].
RESULTS
Production of the mouse IgG2a-type antibody 
PcMab-47
In this study, we first produced a mouse IgG2a-type 
version of PcMab-47 by subcloning appropriate VH and 
VL cDNAs of PcMab-47 and CH and CL of mouse IgG2a 
into pCAG vectors because mouse IgG2a possess high 
ADCC and CDC activities (Figure 1) [36]. The IgG2a-type 
PcMab-47 was designated 47-mG2a.
We further produced 47-mG2a-f (Figure 1). 
Defucosylation was confirmed using lectins such as 
Aleuria aurantia lectin (AAL, fucose binder) [37] and 
Pholiota squarrosa lectin (PhoSL, core fucose binder) [38]. 
Concanavalin A (ConA, mannose binder) [39] was used as 
a control. Both 47-mG2a and 47-mG2a-f were detected using 
ConA (Figure 2A). 47-mG2a, but not 47-mG2a-f, was detected 
using AAL and PhoSL (Figure 2A), indicating that 47-mG2a-f 
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was defucosylated. We also confirmed the defucosylation 
using a lectin microarray (Figure 2B). Although 47-mG2a was 
recognized by core fucose binders such as Aspergillus oryzae 
lectin (AOL) [40], AAL, and Pisum sativum agglutinin (PSA) 
[41], these binders did not detect 47-mG2a-f. 47-mG2a was 
strongly detected using Lens culinaris agglutinin (LCA, 
core fucose and agalactosylated N-glycan binder) [42]; in 
contrast, 47-mG2a-f was moderately detected. Both 47-mG2a 
and 47-mG2a-f were detected using ConA. These results 
indicate that 47-mG2a-f was defucosylated. All anti-PODXL 
antibodies reacted with CHO/hPODXL cells, but not with 
parental CHO-K1 cells (Figure 2C).
We confirmed the PODXL expression in OSCC 
cell lines such as HSC-2, HSC-3, HSC-4, Ca9-22, HO-
1-u-1, and SAS cells using RT-PCR (data not shown). We 
examined the sensitivity of 47-mG2a against these OSCC 
cell lines using flow cytometry. As shown in Figure 3A, 
IgG1-type PcMab-47 recognized endogenous PODXL, 
which is expressed in OSCC cell lines such as HSC-2, HSC-
3, HSC-4, Ca9-22, HO-1-u-1, and SAS cells. PcMab-47 has 
weaker reactivity against HO-1-u-1 cells than against the 
other cell lines. The mouse-human chimeric chPcMab-47 
reacted with OSCC cells similarly as PcMab-47 (Figure 
3B). Furthermore, 47-mG2a and 47-mG2a-f exhibited similar 
reactivity against OSCC cell lines (Figure 3C and 3D). 47-
mG2a and 47-mG2a-f exhibited greater reactivity against HO-
1-u-1 cells, indicating that 47-mG2a and 47-mG2a-f are more 
sensitive for PODXL than PcMab-47. Polyclonal antibody 
against PODXL reacted with all OSCC cell lines although 
the reactivity was lower than PcMab-47 (Figure 3E). 
Another anti-PODXL mAb (clone 53D11) reacted them in 
the similar pattern with PcMab-47.
The binding affinity of mouse IgG2a-type 
PcMab-47
We performed a kinetic analysis of the 
interactions of PcMab-47, chPcMab-47, 47-mG2a, and 
47-mG2a-f with OSCC cells using flow cytometry. As 
shown in Figure 4, the dissociation constant (KD) for 
PcMab-47 against Ca9-22 was 5.1 × 10-8 M. In contrast, 
those for chPcMab-47, 47-mG2a, and 47-mG2a-f were 
2.1 × 10−8, 1.5 × 10−8, and 2.2 × 10−8 M, respectively. 
The binding affinities of chPcMab-47, 47-mG2a, and 
47-mG2a-f against Ca9-22 were 2.4-, 3.4-, and 2.3-
fold higher, respectively, than that of PcMab-47. We 
further determined the KD for PcMab-47 against HSC-2 
and SAS cells. The results were summarized in Table 
1. The binding affinities of chPcMab-47 and 47-mG2a 
for HSC-2 cells were 1.1- and 1.5-fold higher than that 
of PcMab-47, respectively, although 47-mG2a-f had 
lower binding affinity for HSC-2 cells than PcMab-47. 
The binding affinities of chPcMab-47, 47-mG2a, and 
47-mG2a-f for SAS cells were 1.7-, 1.8-, and 1.1-fold 
higher than that of PcMab-47, respectively, indicating 
that all chimeric antibodies, including chPcMab-47, 
47-mG2a, and 47-mG2a-f, possess higher affinity for 
PODXL than the original PcMab-47. The binding 
affinities of 47-mG2a for HSC-2, SAS, and Ca9-22 
cells were 3.1-, 1.6-, and 1.5-fold higher than those of 
47-mG2a-f, respectively, indicating that 47-mG2a has 
greater binding affinity than 47-mG2a-f for OSCC cell 
lines. The difference of binding affinity among cell 
lines was observed probably because the glycosylation 
of PODXL might be different in those OSCC cell lines.
Figure 1: Schematic illustration of PcMab-47, 47-mG2a and 47-mG2a-f. 47-mG2a was produced by subcloning appropriate VH 
and VL cDNAs of PcMab-47 and CH and CL of mouse IgG2a into pCAG vectors. 47-mG2a-f was further produced by defucosylating 47-mG2a.
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Figure 2: Confirmation of the defucosylation of 47-mG2a-f by lectins. (A) Enzyme-linked immunosorbent assay (ELISA) using 
lectins. 47-mG2a and 47-mG2a-f were immobilized and incubated with biotin-labeled lectins such as Aleuria aurantia lectin (AAL), Pholiota 
squarrosa lectin (PhoSL), and concanavalin A (Con A) followed by peroxidase-conjugated streptavidin. The enzymatic reaction was 
produced using a 1-Step Ultra TMB-ELISA. (B) Lectin microarray. AOL, Aspergillus oryzae lectin; PSA, Pisum sativum agglutinin; LCA, 
Lens culinaris agglutinin. (C) Flow cytometry using anti-PODXL antibodies. Cells were treated with PcMab-47 (1 μg/mL), chPcMab-47 
(1 μg/mL), 47-mG2a (1 μg/mL), 47-mG2a-f (1 μg/mL), polyclonal anti-PODXL antibody (10 μg/mL), or 53D11 (10 μg/mL) followed by 
secondary antibodies. Black line, negative control. pAb, polyclonal antibody.
Figure 3: Flow cytometry using anti-PODXL antibodies. Cells were treated with PcMab-47 (1 μg/mL) (A), chPcMab-47 (1 μg/
mL) (B), 47-mG2a (1 μg/mL) (C), 47-mG2a-f (1 μg/mL) (D), polyclonal anti-PODXL antibody (10 μg/mL) (E), or 53D11 (10 μg/mL) (F) 
followed by secondary antibodies. Black line, negative control.
Oncotarget22484www.oncotarget.com
Immunohistochemical analysis of PcMab-47, 47-
mG2a, and 47-mG2a-f in OSCC tissues
We next performed immunohistochemical analysis 
in OSCCs using PcMab-47, 47-mG2a, and 47-mG2a-f. As 
shown in Figure 5A and 5F, PcMab-47 stained OSCCs in 
a cytoplasmic staining pattern; contrarily, no signals were 
observed for the negative control (no primary mAb) in a 
serial section of OSCCs (Figure 5D and 5I). In addition, 
47-mG2a and 47-mG2a-f also stained OSCCs sensitively 
(Figure 5B, 5C, 5G, and 5H). Of interest, the concentration 
used for 47-mG2a and 47-mG2a-f in immunohistochemical 
analysis was 0.5 μg/mL, which was 10-fold lower than that 
for PcMab-47, indicating that 47-mG2a and 47-mG2a-f are 
extremely sensitive for use in OSCC tissues. PcMab-47, 
47-mG2a, and 47-mG2a-f also stained endothelial cells 
around tumor cells (Figure 5F, 5G, and 5H). The 
sensitivity of 47-mG2a and 47-mG2a-f was extremely 
similar in immunohistochemical analysis, and we used 
PcMab-47 and 47-mG2a for further immunohistochemical 
studies.
We stained 201 OSCC samples using PcMab-47 
and 47-mG2a and summarized our findings in Table 2. 
PcMab-47 stained 163/201 (81.1%) OSCC samples. 
Among them, the intensity of staining was 3+ in 11/163 
(6.7%) samples. In contrast, 47-mG2a stained 197/201 
(98.0%) OSCC samples. Among them, the intensity was 
3+ in 15/197 (7.6%) samples, indicating that 47-mG2a is 
more sensitive than PcMab-47 in immunohistochemical 
analyses of OSCCs. All staining results for PcMab-47 and 
47-mG2a are shown in Supplementary Table 1.
We also performed immunohistochemical analysis 
using PcMab-47 and 47-mG2a against normal tongue, 
and checked the PODXL expression in normal squamous 
epithelium. As shown in Figure 6, PODXL was not 
detected in normal squamous epithelium. In contrast, 
PODXL was detected in normal endothelial cells. The 
staining intensity of 47-mG2a was also higher than that 
of PcMab-47 in normal endothelial cells. We further 
checked the cross-reactivity of PcMab-47 against mouse 
PODXL using flow cytometry and immunohistochemistry. 
However, no reaction was observed against mouse 
PODXL (data not shown), indicating that anti-PODXL 
antibodies might not affect the tumor angiogenesis or 
tumor microenvironment in mouse xenograft model.
Functional analysis of PODXL in OSCC cells in 
vitro and in vivo
Next, we investigated whether PODXL is 
associated with tumor phenotype in OSCC cell lines. We 
selected SAS cells for this study because they express 
PODXL at higher levels than other OSCC cells (Figure 
3) and they have been reported to grow extremely well 
Figure 4: Binding affinities of anti-PODXL antibodies were determined using flow cytometry. Ca9-22 cells were suspended 
in 100 μL of serially diluted antibodies (6 ng/mL to 100 μg/mL), and secondary antibodies were then added. Fluorescence data were 
collected using a cell analyzer. GeoMean, geometric mean of fluorescence intensity.
Table 1: KD of anti-PODXL mAbs against OSCC cell lines
PcMab-47 chPcMab-47 47-mG2a 47-mG2a-f
HSC-2 2.3 × 10-8 M 2.1 × 10-8 M 1.5 × 10-8 M 4.6 × 10-8 M
SAS 8.5 × 10-9 M 4.9 × 10-9 M 4.6 × 10-9 M 7.4 × 10-9 M
Ca9-22 5.1 × 10-8 M 2.1 × 10-8 M 1.5 × 10-8 M 2.2 × 10-8 M
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in vivo [43]. As shown in Figure 7A, PcMab-47 did not 
react with PODXL-knockout (KO) SAS cells (SAS/
hPODXL-KO). To examine the migratory and invasive 
abilities of SAS/hPODXL-KO cells, we performed 
wound-healing and invasion assays, respectively, but 
no significant differences in migration (Figure 7B) and 
invasion (Figure 7C) were identified between parental 
and SAS/hPODXL-KO cells. We next investigated 
whether PODXL is associated with the growth of OSCC 
cell lines in vitro using the MTS assay. The growth of 
three SAS/hPODXL-KO cell lines was lower than that of 
parental SAS cells (Figure 7D). We further investigated 
whether PODXL affects OSCC tumor growth in vivo by 
comparing the growth of SAS and three SAS/hPODXL-
KO cell lines that were transplanted subcutaneously into 
nude mice. As shown in Figure 7E, the growth of SAS/
Figure 5: Immunohistochemical analysis of anti-PODXL antibodies in oral squamous cell carcinomas. Tissue sections 
(obtained from Case 174) were incubated with 5 μg/mL PcMab-47 (A, F), 0.5 μg/mL of 47-mG2a (B, G), 0.5 μg/mL 47-mG2a-f (C, H), or 
control (blocking buffer; D, I) for 1 h at room temperature followed by treatment with an Envision+ kit for 30 min. Color was developed 
using 3,3-diaminobenzidine tetrahydrochloride for 2 min, and sections were then counterstained with hematoxylin. (E, J) Hematoxylin & 
eosin staining. Arrows: endothelial cells. Scale bar = 100 μm.
Table 2: Summary of anti-PODXL immunostaining in OSCC
Score No. of positive cases Positive rate (%)
- 1+ 2+ 3+
PcMab-47 38 120 32 11 163/201 81.1
47-mG2a 4 134 48 15 197/201 98.0
The intensity of staining was evaluated as -, 1+, 2+, or 3+.
Oncotarget22486www.oncotarget.com
Figure 6: Immunohistochemical analysis of anti-PODXL antibodies in normal tongue. Tissue sections of normal tongue 
were incubated with 5 μg/mL PcMab-47 (A, D) and 0.5 μg/mL of 47-mG2a (B, E) for 1 h at room temperature followed by treatment with an 
Envision+ kit for 30 min. Color was developed using 3,3-diaminobenzidine tetrahydrochloride for 2 min. Sections were then counterstained 
with hematoxylin. (C, F) Hematoxylin & eosin staining. Arrows: endothelial cells. Scale bar = 100 μm.
Figure 7: Functional analysis of PODXL in vitro and in vivo using PODXL-knockout (KO) oral squamous cell 
carcinoma cell lines. (A) Flow cytometry. Cells were treated with 10 μg/mL PcMab-47 followed by secondary antibodies. Black line, 
negative control. (B) Evaluation of cell migration. A wound-healing assay was performed to examine the effects of PODXL-KO on SAS 
cell migration. Images of wounded cell monolayers taken at 0 and 8 h. The vertical lines indicate the wound edge. (C) Evaluation of cell 
invasion using the Transwell invasion assay. The histogram indicates the average of three experiments (values are means ± SEM) and shows 
the invasion ratio normalized to the value in parental SAS cells. n.s., not significant. (D) The MTS assay was performed to determine cell 
growth. The values are means ± SEM. An asterisk indicates statistical significance between SAS and SAS/hPODXL-KO cells (***P < 0.005, 
two-tailed Student’s t-test). (E) In vivo analysis. SAS and SAS/hPODXL-KO cells were injected subcutaneously into female nude mice. 
The tumor volume was measured at day 21. The values are means ± SEM. An asterisk indicates statistical significance between SAS and 
SAS/hPODXL-KO cells (*P < 0.05, two-tailed Student’s t-test).
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hPODXL-KO cells was lower than that of parental SAS 
cells.
Furthermore, we investigated the effect of PODXL 
on the growth of 3D cells with cancer stem cell-like 
properties. The 3D growth of three SAS/hPODXL-KO cell 
lines tended to decrease, and the growth of SAS/hPODXL-
KO#23 cells was significantly inhibited after incubation 
for 72 h, indicating that PODXL has tumorigenic potential 
and might be associated with tumorigenicity in vivo 
(Figure 8A and 8B). In contrast, there are little effects by 
anti-PODXL antibodies on 3D cell proliferation in vitro 
(Figure 8C).
ADCC and CDC activities of 47-mG2a and 
47-mG2a-f
We investigated whether 47-mG2a and 47-mG2a-f can 
induce ADCC and CDC in PODXL-expressing cell lines. 
Both 47-mG2a and 47-mG2a-f induced CDC against CHO/
hPODXL (Figure 9A), whereas they showed faint ADCC 
against CHO/hPODXL cells (data not shown), indicating 
that only CDC is critical for the antitumor activity of 
47-mG2a-f against CHO/hPODXL cells.
47-mG2a-f induced ADCC activity against HSC-
2, whereas 47-mG2a did not (Figure 9B). Furthermore, 
higher ADCC was observed by 47-mG2a-f against SAS 
cells compared with 47-mG2a (Figure 9C). These results 
indicate that depletion of core-fucose is important for 
inducing ADCC against OSCC cells. Neither 47-mG2a 
nor 47-mG2a-f induced CDC in OSCC cell lines (data 
not shown), indicating that only ADCC is critical for the 
antitumor activity of 47-mG2a-f against OSCC cells.
Antitumor activity of 47-mG2a and 47-mG2a-f 
against OSCC xenografts
To study the antitumor effects of 47-mG2a and 
47-mG2a-f on primary tumor growth in vivo, CHO/
hPODXL cells were subcutaneously implanted into 
the flanks of nude mice. 47-mG2a and 47-mG2a-f, and 
mouse IgG (control) were injected twice (100 μg of the 
antibodies on days 1 and 9 after cell inoculation) into the 
peritoneal cavity of mice. Tumor formation was observed 
in all groups. Both 47-mG2a and 47-mG2a-f significantly 
reduced tumor development compared with IgG on 
day 16 (Figure 10A). The tumor weights of mice in the 
both 47-mG2a and 47-mG2a-f groups were significantly 
lower than that in the IgG group (Figure 10B). Body 
weight was not significantly different among the three 
groups (Supplementary Figure 1A and 1B). The resected 
tumors of CHO/hPODXL xenografts are depicted in 
Supplementary Figure 1C. No difference was illustrated 
among those groups using hematoxylin & eosin (HE) 
staining (Supplementary Figure 2). Both 47-mG2a and 
47-mG2a-f showed the similar results in CHO/hPODXL 
xenograft models because those mAbs might exert CDC 
activities against CHO/hPODXL, and might not exert 
ADCC activities in vivo.
We also investigated the antitumor activity of 47-
mG2a and 47-mG2a-f using HSC-2 xenograft models. 
47-mG2a and 47-mG2a-f, and mouse IgG (control) were 
injected three times (100 μg of the antibodies on days 1, 
7, and 14 after cell injections) into the peritoneal cavity 
of mice. Tumor formation was observed in all groups. 
47-mG2a-f significantly reduced tumor development 
compared with IgG on day 20 (Figure 11A). Although 
47-mG2a also reduced tumor development compared 
with IgG, the result was not significant, indicating that 
the depletion of core fucose is critical for the antitumor 
activity of 47-mG2a-f against HSC-2 xenograft models. 
The tumor weight of mice in the 47-mG2a-f group was 
significantly lower than that in the IgG group (Figure 
11B). Conversely, 47-mG2a was not associated with a 
significant decrease in tumor weight versus IgG. However, 
body weight was not significantly different among the 
three groups (Supplementary Figure 3A and 3B). The 
resected tumors of HSC-2 xenografts are depicted in 
Supplementary Figure 3C. No difference was illustrated 
among those groups using HE staining (Supplementary 
Figure 4).
We further investigated the antitumor activity of 47-
mG2a and 47-mG2a-f using SAS xenograft models. In this 
study, we injected 100 μg of the antibodies three times. 
As shown in Figure 12A, 47-mG2a-f, but not 47-mG2a, 
significantly reduced tumor development compared with 
IgG on day 20, indicating that the depletion of core fucose 
is also critical for antitumor activity of 47-mG2a-f against 
SAS xenograft models. Tumor weight was significantly 
lower in the 47-mG2a-f group than in the IgG group (Figure 
12B). Conversely, 47-mG2a was not linked to decreases in 
tumor weight. Body weight was similar among the three 
groups (Supplementary Figure 5A and 5B). The resected 
tumors of SAS xenografts are shown in Supplementary 
Figure 5C. No difference in HE staining was identified 
among the groups (Supplementary Figure 6).
We performed dose-escalation studies using CHO/
hPODXL xenograft models (Supplementary Figure 
7). In this study, we injected 500 μg of the antibodies 
twice. As shown in Supplementary Figure 7A, both 
47-mG2a and 47-mG2a-f significantly reduced tumor 
development compared with IgG on day 16 (P < 0.01). 
The resected tumors of CHO/hPODXL xenografts are 
shown in Supplementary Figure 7B. Tumor weights were 
significantly lower in the 47-mG2a and 47-mG2a-f groups 
than in the IgG group (Supplementary Figure 7C). Body 
weight was similar among the three groups (data not 
shown), as were HE staining patterns (Supplementary 
Figure 7D). In CHO/hPODXL xenograft models, dose-
escalation was not necessary because 100 μg of the 
antibodies twice showed enough anti-tumor activities.
We further performed dose-escalation studies using 
HSC-2 xenograft models because we could not observe 
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Figure 8: Proliferation of SAS and SAS/hPODXL-KO cells on 3D cultures and the influence of anti-PODXL antibodies 
on the 3D cell proliferation. (A) 3D cell proliferation was measured by 3D cell proliferation assay. The graphs show the relative cell 
growth in 3D culture at 24, 48, and 72 h. Each bar represents the mean ± SEM. An asterisk indicates statistical significance (**P < 0.01, 
Tukey-Kramer’s test). (B) Optical microscopic images of SAS and SAS/hPODXL-KO cells after 72 h incubation. Scale bar, 200 μm. (C) 
3D cell proliferation treated with or without anti-hPODXL antibodies (47-mG2a and 47-mG2a-f) for 72 h. The values are means ± SEM.
Figure 9: Complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) of anti-
PODXL mAbs against PODXL-expressing cell lines. (A) CDC was evaluated using the 51Cr release assay. Target cells were 
incubated with [51Cr]sodium chromate (0.1 μCi) for 1 h at 37°C. The 51Cr-labeled cells were incubated with a baby rabbit complement at a 
dilution of 1:4 in the presence of 47-mG2a, 47-mG2a-f, or control mouse IgG (10 μg/mL) for 6 h in 96-well plates. 
51Cr release was measured 
in the supernatant. (B, C) ADCC was determined using the 51Cr release assay. Target cells such as HSC-2 (B) and SAS (C) were incubated 
with [51Cr]sodium chromate. After washing, 51Cr-labeled target cells were placed in 96-well plates in triplicate. Effector cells and 47-mG2a, 
47-mG2a-f, or control mouse IgG were added to the plates. After incubation (6, 12, and 18 hrs), 
51Cr release was measured in the supernatant. 
The values are means ± SEM. *P < 0.05, **P < 0.01 t-test.
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Figure 10: Antitumor activity of 47-mG2a and 47-mG2a-f against CHO/hPODXL. (A) Tumor volume of CHO/hPODXL 
xenografts. CHO/hPODXL cells were injected subcutaneously into female nude mice. The indicated antibodies (100 μg/day; 5 mg/kg) were 
administered intraperitoneally 1 and 9 days after cancer cell inoculation. The tumor volume was measured at the indicated time points. The 
values are means ± SEM. (B) Tumor weight of CHO/hPODXL xenografts (day 16). The values are means ± SEM. An asterisk indicates 
statistical significance (*P < 0.05, **P < 0.01, Tukey-Kramer’s test).
Figure 11: Antitumor activity of 47-mG2a and 47-mG2a-f against HSC-2 xenografts. (A) Tumor volume of HSC-2 xenografts. 
HSC-2 cells were injected subcutaneously into female nude mice. The indicated antibodies (100 μg/day; 5 mg/kg) were administered 
intraperitoneally 1, 7, and 14 days after cancer cell inoculation. The tumor volume was measured at the indicated time points. The values are 
means ± SEM. (B) Tumor weight of HSC-2 xenografts (day 20). An asterisk indicates statistical significance (*P < 0.05, Tukey-Kramer’s 
test).
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sufficient antitumor activity after three injections of 100 
μg of the antibodies. In this study, we injected 500 μg of 
the antibodies twice. As shown in Figure 13A and 13B, 
both 47-mG2a and 47-mG2a-f reduced tumor development 
compared with control mouse IgG on day 15 (P < 0.01). 
Furthermore, 47-mG2a-f exhibited greater antitumor 
activity than 47-mG2a, but it is not significant (Figure 
13B). The resected tumors of HSC-2 xenografts are 
shown in Figure 14A. Tumor weights were significantly 
lower in the both 47-mG2a and 47-mG2a-f group than in 
the IgG group (Figure 14B). Body weight was similar 
among the three groups (data not shown), as were HE 
staining patterns (Supplementary Figure 8). These 
results indicate that 47-mG2a-f showed higher anti-
tumor activities against HSC-2 due to its higher ADCC 
against PODXL-expressing OSCCs, and dose-escalation 
was effective for those anti-tumor activities in HSC-2 
xenograft models.
We finally performed dose-escalation studies using 
SAS xenograft models because we could not observe 
sufficient antitumor activity after three injections of 100 
μg of the antibodies (Supplementary Figure 9). In this 
study, we injected 500 μg of the antibodies three times. As 
shown in Supplementary Figure 9A, 47-mG2a-f reduced 
tumor development compared with control mouse IgG 
on day 21 (P < 0.05) and exhibited significantly greater 
antitumor activity than 47-mG2a. The resected tumors of 
SAS xenografts are shown in Supplementary Figure 9B. 
Tumor weight was significantly lower in the 47-mG2a-f 
group than in the IgG group, whereas 47-mG2a did not 
reduce tumor weight (Supplementary Figure 9C). Body 
weight was similar among the three groups (data not 
shown), as were HE staining patterns (Supplementary 
Figure 9D). These results indicate that 47-mG2a-f showed 
higher anti-tumor activities due to its higher ADCC 
against PODXL-expressing OSCCs, but dose-escalation 
was not sufficient for those anti-tumor activities in vivo.
DISCUSSION
47-mG2a and 47-mG2a-f showed higher binding 
activity compared with its original PcMab-47 (Figure 4). 
We have sometimes experienced that chimeric antibodies 
possesses much higher affinity or lower affinity compared 
with original monoclonal antibodies [34, 44-49]. The 
stability of antibodies might be different among constant 
regions. Although 47-mG2a exhibited ADCC activity 
against SAS cells (Figure 9C), this activity is not sufficient 
to induce antitumor activity in vivo (Figure 12). Then, 
we produced a non-fucosylated version of 47-mG2a 
(47-mG2a-f) to augment its ADCC activities because non-
fucosylated antibodies are known to show higher ADCC 
activities [35, 50]. As expected, 47-mG2a-f exhibited 
stronger ADCC activities than 47-mG2a against OSCC 
cells (Figure 9B and 9C), leading to higher antitumor 
activities in HSC-2 and SAS xenograft models (Figure 11 
Figure 12: Antitumor activity of 47-mG2a and 47-mG2a-f against SAS xenografts. (A) Tumor volume of SAS xenografts. 
SAS cells were injected subcutaneously into female nude mice. The indicated antibodies (100 μg/day; 5 mg/kg) were administered 
intraperitoneally 1, 7, and 14 days after cancer cell inoculation. The tumor volume was measured at the indicated time points. The values are 
means ± SEM. (B) Tumor weight of SAS xenografts (day 20). An asterisk indicates statistical significance (*P < 0.05, Tukey-Kramer’s test).
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and 12). In contrast, three injections were not effective 
despite a dose of 5 mg/kg, which corresponded to 100 
μg/mouse in this study and exceeded the usual dose of 
antibody therapy [51, 52]. Then, two injections of 500 
μg/mouse, corresponding to 25 mg/kg, resulted in greater 
antitumor activities in HSC-2 xenograft models (Figure 
13), indicating that dose escalation might be necessary 
for monotherapy using anti-PODXL antibodies although 
Figure 13: Antitumor activity of 47-mG2a and 47-mG2a-f against HSC-2 xenografts (500 μg/day; 25 mg/kg). (A) 
Comparison of the tumor size and tumor incidence of HSC-2 xenograft in nude mice (day 15). (B) Tumor volume of HSC-2 xenografts. 
HSC-2 cells were injected subcutaneously into female nude mice. The indicated antibodies (500 μg/day; 25 mg/kg) were administered 
intraperitoneally 1 and 7 days after cancer cell inoculation. The tumor volume was measured at the indicated time points. The values are 
means ± SEM. An asterisk indicates statistical significance (**P < 0.01, Tukey-Kramer’s test).
Figure 14: Antitumor activity of 47-mG2a and 47-mG2a-f against HSC-2 xenografts (500 μg/day; 25 mg/kg). (A) 
Comparison of tumor size (day 15). (B) Tumor weight of HSC-2 xenografts (day 15). An asterisk indicates statistical significance (**P < 
0.01, Tukey-Kramer’s test).
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dose-escalation was not sufficient for SAS xenograft 
models (Supplementary Figure 9). Furthermore, we need 
to combine anti-PODXL antibodies with anti-cancer drugs 
or include them in novel antitumor regimens, including 
T cells and viruses, to exert antitumor activity against 
cancer cells. Previously, we produced chPcMab-47, a 
mouse-human chimeric antibody, which could be applied 
to cancer patients [34]. chPcMab-47 exerted ADCC and 
CDC activity and showed antitumor activities in mouse 
xenograft models. Because 47-mG2a-f showed much 
higher ADCC activity in this study, we also need to 
produce core-fucose-deficient chPcMab-47 in the future 
study.
Jing et al. reported that high PODXL expression was 
significantly associated with worse OS and was predictive 
of shorter OS in multiple cancers, especially pancreatic 
and colorectal cancers [53]. They also revealed that 
high PODXL expression predicted worse DSS and DFS, 
although European patients were included in this analysis. 
These results suggest PODXL could be a prognostic 
factor, and diagnostic tools targeting this protein are 
expected. Because the association between PODXL 
expression and clinical stage has not been investigated 
in OSCC, it was analyzed in the current study. However, 
PODXL expression in stages III–IV was not significantly 
higher than that in stages I–II in patients with OSCC (data 
not shown). Further investigation regarding the clinical 
importance of PODXL expression in more patients with 
OSCC is needed.
Taken together, anti-PODXL antibodies could be 
useful antibody therapies against PODXL-expressing 
OSCCs. PODXL is known to be expressed in kidney, 
heart, pancreas, and breast tissues, and it plays important 
roles in those tissues [22]. Recently, we successfully 
produced cancer-specific mAbs (CasMabs) against human 
podoplanin [16, 54]. Using the same methods, we need to 
develop CasMabs against PODXL in the near future.
MATERIALS AND METHODS
Cell lines
HSC-2 (oral squamous carcinoma from oral cavity), 
HSC-3 (oral squamous carcinoma cell line from tongue 
with high metastatic potential), HSC-4 (oral squamous 
carcinoma cell line from tongue), Ca9-22 (oral squamous 
carcinoma from gingiva), HO-1-u-1 (oral squamous 
carcinoma from mouth floor), and SAS (oral squamous 
carcinoma cell line from tongue) were obtained from the 
Japanese Collection of Research Bioresources Cell Bank 
(Osaka, Japan). CHO-K1 was obtained from the American 
Type Culture Collection (ATCC, Manassas, VA). CHO/
hPODXL was produced in our previous study [17]. The 
CHO-S cell line was purchased from Thermo Fisher 
Scientific Inc. (Waltham, MA, USA). PDIS-5 (core fucose 
KO CHO-S) cells were established previously [48]. SAS/
hPODXL-KO cells were produced using CRISPR/Cas9 
plasmids (Target ID: HS0000056763) targeting human 
PODXL (Sigma-Aldrich Corp., St. Louis, MO, USA). 
HSC-2, HSC-3, HSC-4, Ca9-22, HO-1-u-1, SAS and SAS/
hPODXL-KO cells were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM; Nacalai Tesque, Kyoto, 
Japan), and CHO-K1 and CHO/hPODXL were cultured 
in RPMI 1640 medium (Nacalai Tesque), supplemented 
with 10% heat-inactivated fetal bovine serum (Thermo 
Fisher Scientific Inc.), 100 units/mL penicillin, 100 μg/
mL streptomycin, and 25 μg/mL amphotericin B (Nacalai 
Tesque) at 37°C in a humidified atmosphere containing 
5% CO2 and 95% air.
Tissues
Cancer tissue microarrays of oral cancers were 
purchased from US Biomax (Rockville, MD, USA) and 
Cybrdi (Frederick, MD, USA). This study examined 53 
patients with oral cancer who underwent surgery at Tokyo 
Medical and Dental University. The Tokyo Medical and 
Dental University Institutional Review Board reviewed 
and approved the use of human cancer tissues. Written 
informed consent was obtained for the use of human 
cancer tissue samples.
Antibodies
PcMab-47, a mouse anti-PODXL mAb (IgG1, 
kappa), was developed as previously described [17]. 
Mouse IgG was purchased from Sigma-Aldrich. To 
generate 47-mG2a, appropriate VH and VL cDNAs of mouse 
PcMab-47 and CH and CL of mouse IgG2a were subcloned 
into pCAG-Ble and pCAG-Neo vectors (Wako Pure 
Chemical Industries, Osaka, Japan), respectively. Antibody 
expression vectors were transfected into ExpiCHO-S cells 
using the ExpiCHO Expression System (Thermo Fisher 
Scientific). To generate 47-mG2a-f, antibody expression 
vectors were also transfected into PDIS-5 cells using 
the ExpiCHO Expression System. Stable transfectants 
of chPcMab-47 cells were established previously [34]. 
CHO-S/chPcMab-47 cells were cultivated in CHO-S-
SFM II medium (Thermo Fisher Scientific). PcMab-47, 
47-mG2a, 47-mG2a-f, and chPcMab-47 were purified 
using Protein G-Sepharose (GE Healthcare Bio-Sciences, 
Pittsburgh, PA, USA). Goat polyclonal anti-human 
PODXL and mouse monoclonal anti-human PODXL 
mAb (53D11) were purchased from R&D systems, Inc. 
(Minneapolis, MN) and Medical & Biological Laboratories 
Co., Ltd. (MBL; Nagoya, Japan), respectively.
Enzyme-linked immunosorbent assay (ELISA)
47-mG2a and 47-mG2a-f were immobilized on 
Nunc Maxisorp 96-well immunoplates (Thermo Fisher 
Scientific) at 1 μg/mL for 30 min. After blocking using 
SuperBlock buffer (Thermo Fisher Scientific) with 
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0.5 mM CaCl2, the plates were incubated with biotin-
labeled lectins, such as AAL (Vector Laboratories, 
Burlingame, CA, USA), PhoSL (J-OIL MILLS, Inc., 
Tokyo, Japan) [38], and ConA (Vector Laboratories), 
followed by 1:3000 diluted peroxidase-conjugated 
streptavidin (Agilent Technologies, Santa Clara, CA, 
USA). The enzymatic reaction was produced using a 
1-Step Ultra TMB-ELISA (Thermo Fisher Scientific). The 
optical density was measured at 655 nm using an iMark 
microplate reader (Bio-Rad Laboratories, Inc., Berkeley, 
CA).
Lectin microarray
47-mG2a and 47-mG2a-f (100 μL; 31.25–2000 ng/
mL) were applied to a lectin array (LecChip ver. 1.0; 
GlycoTechnica, Hokkaido, Japan), including triplicate 
spots of 45 lectins in each of seven incubation baths on the 
glass slide. After incubation at 20°C for 17 h, the reaction 
solution was discarded. The glass slide was scanned using 
a GlycoStation Reader 1200 (GlycoTechnica).
Flow cytometry
Cell lines were harvested via a brief exposure to 
0.25% trypsin/1 mM ethylenediaminetetraacetic acid 
(Nacalai Tesque). After washing with 0.1% bovine-serum 
albumin in phosphate-buffered saline (Nacalai Tesque), 
cells were treated with primary mAbs for 30 min at 4°C, 
followed by treatment with Alexa Fluor 488-conjugated 
anti-mouse IgG (1:1000; Cell Signaling Technology, 
Danvers, MA, USA), FITC-labeled goat anti-human 
IgG (1:1000; Thermo Fisher Scientific), or FITC-labeled 
rabbit anti-goat IgG (1:1000; Thermo Fisher Scientific). 
Fluorescence data were collected using an EC800 Cell 
Analyzer (Sony Corp., Tokyo, Japan).
Determination of binding affinity using flow 
cytometry
HSC-2, SAS, and Ca9-22 cells (2 × 105) were 
resuspended in 100 μL of serially diluted PcMab-47, 47-
mG2a, 47-mG2a-f, or chPcMab-47 (6 ng/mL to 100 μg/mL), 
followed by the addition of secondary anti-mouse IgG 
(Cell Signaling Technology) or anti-human IgG (Thermo 
Fisher Scientific). Fluorescence data were collected using 
a cell analyzer (EC800). KD was obtained by fitting the 
binding isotherms using the built-in one-site binding 
models in GraphPad PRISM 6 (GraphPad Software, La 
Jolla, CA, USA).
Immunohistochemical analyses
Histologic sections (4 μm thick) were deparaffinized 
in xylene and then rehydrated and autoclaved in citrate 
buffer (pH 6.0; Agilent Technologies Inc.) for 20 min. 
Sections were then incubated with 0.5–5 μg/mL primary 
mAbs for 1 h at room temperature and then treated 
using an Envision+ kit (Agilent Technologies) for 30 
min. Color was developed using 3,3-diaminobenzidine 
tetrahydrochloride (Agilent Technologies) for 2 min, 
and sections were then counterstained with hematoxylin 
(Wako Pure Chemical Industries Ltd.). The intensity of 
staining was evaluated as −, 1+, 2+, or 3+.
Proliferation assay in vitro
Cell proliferation in vitro was measured using MTS 
tetrazolium (Cell Titer 96 Aqueous, Promega, Madison, 
WI, USA). Cells were plated (500 cells/100 μL/well) in 
triplicate in 96-well plates. Cell viability was measured 
every 24 h for 96 h. After adding 20 μL of MTS to 
the wells followed by a 1-h incubation at 37°C, the 
absorbance at 490 nm (reference, 630 nm) was read using 
a microplate reader (Power Scan HT, Bio Tek Instruments, 
Winooski, VT, USA). The mean absorbance of the 3-well 
set was obtained from 0 to 96 h. Statistical significance 
was analyzed using the standard Student’s t-test. P-values 
<0.05 were considered statistically significant.
Proliferation assay in vivo
Five-week-old female BALB/c nude mice were 
purchased from Charles River (Kanagawa, Japan). Seven-
week-old mice were used for the in vivo proliferation 
assay. Cells (0.3 mL of 1.33 × 108 /mL in DMEM) were 
mixed with 0.5 mL of BD Matrigel Matrix Growth Factor 
Reduced (BD Biosciences, San Jose, CA, USA). A 100 
μL suspension (containing 5 × 106 cells) was injected 
subcutaneously into the left flanks of nude mice. The 
tumor diameter was measured using calipers, and the 
tumor volume was calculated using the following formula: 
volume = W2 × L/2, where W is the short diameter and L is 
the long diameter. The mice were euthanized 21 days after 
cell implantation. All data were expressed as the mean 
± SEM. Statistical analysis was performed using a two-
tailed Student’s t-test. P-values <0.05 were considered 
statistically significant.
Invasion assay
The invasion assay was performed using a 
Cytoselect 96-well Collagen Cell Invasion Assay Kit 
(Cell Biolabs, San Diego, CA, USA) according to the 
manufacturer’s instructions. Cells (2.5 × 104) were pre-
incubated in DMEM containing 0.5% FBS for 12 h, 
washed with serum-free DMEM, and added to the top 
insert of a chamber containing a polycarbonate membrane 
with 8-μm pores coated with a layer of bovine type I 
collagen matrix. The lower chamber was filled with 
DMEM containing 10% FBS as the chemoattractant. 
The assembled chambers were then placed in the 
CO2 incubator for 20 h. Cells that passed through the 
membrane pores were lysed and quantitated using a 
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fluorescence dye-containing solution and a fluorescence 
plate reader. Statistical significance was analyzed using the 
standard Student’s t-test. P-values <0.05 were considered 
statistically significant.
Wound-healing assay
Cells were grown to confluence in DMEM 
containing 0.5% FBS in 6-well plates. Scratch wounds 
were made using 10-μL sterile pipette tips. The cells 
were incubated in DMEM containing 10% FBS for the 
indicated times. Images were captured using an Evolution 
MP camera (Media Cybernetics, Rockville, MD, USA).
3D cell proliferation assay
3D cell proliferation in vitro was measured using 
the CellTiter-Glo® 3D cell viability assay (Promega) 
according to the manufacturer’s instructions [55]. Briefly, 
the cells were plated (500 cells/100 μL/well) in triplicate 
in 96-well ultra low attachment plates (Costar Corning, 
Schiphol-Rijk, Netherlands) with DMEM containing 10% 
FBS. The 3D cell viability was measured every 24 h for 72 
h. The CellTiter-Glo® 3D reagent was added into wells in 
a 1:1 dilution (100 μL volume in well: 100 μL of reagent) 
and then the solutions were mixed well by pipetting. After 
incubation for 30 min at 37°C, the luminescent signal was 
read using an EnSpire multi-plate reader (Perkin Elmer, 
PerkinElmer, Waltham, MA, USA). Images were captured 
using an Evolution MP camera (Media Cybernetics). In 
addition, to investigate the influence of the antibodies 
on the 3D cell proliferation, the cells were plated as 
described above with or without the antibodies (30 μg/
ml). The proliferation rate was calculated relative to the 
signal at 0 h.
ADCC
ADCC was examined using the 51Cr-release assay. 
Effector cells were prepared as previously described [36]. 
Mouse splenocytes were harvested from spleens of six-
week-old male SCID mice. Spleens were homogenized in 
RPMI 1640 and centrifuged. To deplete red blood cells, 
the cell pellet was suspended in red blood cell lysis buffer 
(Sigma-Aldrich). After washing and re-suspension in 10% 
FBS/RPMI1640, splenocytes were used as effector cells. 
Target cells were incubated with 0.1 μCi of [51Cr]sodium 
chromate at 37°C for 1 h. After three washes with 10% 
FBS/RPMI1640, 51Cr-labeled target cells were placed in 
96-well plates in triplicate. Effector cells and antibodies 
(10 μg/ml) were added to the plates (E/T ratio = 100). After 
6, 12, and 18 hrs of incubation, 51Cr release was measured 
in the supernatant (100 μL) from each well using a gamma 
counter (PerkinElmer). The percentage of cytotoxicity was 
calculated using the following formula: % specific lysis = 
(E – S)/(M − S) × 100, where E is the 51Cr release in the 
test sample, S is the spontaneous release, and M is the 
maximum release. Statistical significance was analyzed 
using the standard Student’s t-test. P-values <0.05 were 
considered statistically significant.
CDC
CDC was evaluated using the 51Cr release assay. 
Target cells were incubated with [51Cr]sodium chromate 
(0.1 μCi) for 1 h at 37°C. The cells were then washed 
with 10% FBS/RPMI1640. The 51Cr-labeled cells were 
incubated with a baby rabbit complement Cedarlane 
(Ontario, Canada) at a dilution of 1:4 in the presence 
of antibodies (10 μg/mL) for 6 h in 96-well plates. 
After the incubation, 51Cr radioactivity was measured 
in the supernatants using a gamma counter. The percent 
cytotoxicity was calculated using the following formula: 
% specific lysis = (E – S)/(M − S) × 100, where E is the 
release in the test sample, S is the spontaneous release, 
and M is the maximum release. Statistical significance 
was analyzed using the standard Student’s t-test. P-values 
< 0.05 were considered statistically significant.
Antitumor activity of anti-PODXL antibodies
Five-week-old female BALB/c nude mice were 
purchased from Charles River and used in experiments at 7 
weeks of age. Cells (0.3 mL of 1.33 × 108 /mL in DMEM) 
were mixed with 0.5 mL of BD Matrigel Matrix Growth 
Factor Reduced (BD Biosciences). A 100-μL suspension 
(containing 5 × 106 cells) was injected subcutaneously 
into the right flanks of nude mice. After 1 day, 100 μg 
or 500 μg of 47-mG2a, 47-mG2a-f, or mouse IgG in 200 
μL PBS were injected into the peritoneal cavity of each 
mouse. Additional antibodies were injected once weekly 
for several weeks. The tumor diameter and tumor volume 
were determined as previously described. The mice were 
euthanized 15, 16, 20, or 21 days after cell implantation. 
All data were expressed as the mean ± SEM. Statistical 
analysis was performed using the Tukey-Kramer test. 
P-values < 0.05 was considered statistically significant.
Abbreviations
AAL  Aleuria aurantia lectin
ADCC  Antibody-dependent cellular cytotoxicity
CDC  Complement-dependent cytotoxicity
DFS  Disease-free survival
DMEM  Dulbecco’s Modified Eagle’s Medium
DSS  Disease-specific survival
EGFR  Epidermal growth factor receptor
ELISA  Enzyme-linked immunosorbent assay
HE  Hematoxylin & eosin
HNC  Head and neck cancer
 HNSCC  Head and neck squamous cell 
carcinoma 
LCA  Lens culinaris agglutinin
OS  Overall survival
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OSCC  Oral squamous cell carcinoma
PhoSL  Pholiota squarrosa lectin
PSA  Pisum sativum agglutinin
R/M  Recurrent and/or metastatic.
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